IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-47328-y.html
   My bibliography  Save this article

Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection

Author

Listed:
  • Hadas Tamir

    (Israel Institute for Biological Research)

  • Tal Noy-Porat

    (Israel Institute for Biological Research)

  • Sharon Melamed

    (Israel Institute for Biological Research)

  • Lilach Cherry-Mimran

    (Israel Institute for Biological Research)

  • Moria Barlev-Gross

    (Israel Institute for Biological Research)

  • Ron Alcalay

    (Israel Institute for Biological Research)

  • Yfat Yahalom-Ronen

    (Israel Institute for Biological Research)

  • Hagit Achdout

    (Israel Institute for Biological Research)

  • Boaz Politi

    (Israel Institute for Biological Research)

  • Noam Erez

    (Israel Institute for Biological Research)

  • Shay Weiss

    (Israel Institute for Biological Research)

  • Ronit Rosenfeld

    (Israel Institute for Biological Research)

  • Eyal Epstein

    (Israel Institute for Biological Research)

  • Ohad Mazor

    (Israel Institute for Biological Research)

  • Efi Makdasi

    (Israel Institute for Biological Research)

  • Nir Paran

    (Israel Institute for Biological Research)

  • Tomer Israely

    (Israel Institute for Biological Research)

Abstract

The eradication of smallpox was officially declared by the WHO in 1980, leading to discontinuation of the vaccination campaign against the virus. Consequently, immunity against smallpox and related orthopoxviruses like Monkeypox virus gradually declines, highlighting the need for efficient countermeasures not only for the prevention, but also for the treatment of already exposed individuals. We have recently developed human-like monoclonal antibodies (mAbs) from vaccinia virus-immunized non-human primates. Two mAbs, MV33 and EV42, targeting the two infectious forms of the virus, were selected for in vivo evaluation, based on their in vitro neutralization potency. A single dose of either MV33 or EV42 administered three days post-infection (dpi) to BALB/c female mice provides full protection against lethal ectromelia virus challenge. Importantly, a combination of both mAbs confers full protection even when provided five dpi. Whole-body bioimaging and viral load analysis reveal that combination of the two mAbs allows for faster and more efficient clearance of the virus from target organs compared to either MV33 or EV42 separately. The combined mAbs treatment further confers post-exposure protection against the currently circulating Monkeypox virus in Cast/EiJ female mice, highlighting their therapeutic potential against other orthopoxviruses.

Suggested Citation

  • Hadas Tamir & Tal Noy-Porat & Sharon Melamed & Lilach Cherry-Mimran & Moria Barlev-Gross & Ron Alcalay & Yfat Yahalom-Ronen & Hagit Achdout & Boaz Politi & Noam Erez & Shay Weiss & Ronit Rosenfeld & E, 2024. "Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47328-y
    DOI: 10.1038/s41467-024-47328-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-47328-y
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-47328-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Ronit Rosenfeld & Tal Noy-Porat & Adva Mechaly & Efi Makdasi & Yinon Levy & Ron Alcalay & Reut Falach & Moshe Aftalion & Eyal Epstein & David Gur & Theodor Chitlaru & Einat B. Vitner & Sharon Melamed , 2021. "Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody," Nature Communications, Nature, vol. 12(1), pages 1-9, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47328-y. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.